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iron stored in ferritin is chemically 
reduced in the presence of 
aggregating Aβ(1-42)
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Jon Dobson4,5, Joanna F. collingwood2 & Neil D. telling1
Atypical low-oxidation-state iron phases in Alzheimer’s disease (AD) pathology are implicated in 
disease pathogenesis, as they may promote elevated redox activity and convey toxicity. However, the 
origin of low-oxidation-state iron and the pathways responsible for its formation and evolution remain 
unresolved. Here we investigate the interaction of the AD peptide β-amyloid (Aβ) with the iron storage 
protein ferritin, to establish whether interactions between these two species are a potential source of 
low-oxidation-state iron in AD. Using X-ray spectromicroscopy and electron microscopy we found that 
the co-aggregation of Aβ and ferritin resulted in the conversion of ferritin’s inert ferric core into more 
reactive low-oxidation-states. Such findings strongly implicate Aβ in the altered iron handling and 
increased oxidative stress observed in AD pathogenesis. These amyloid-associated iron phases have 
biomarker potential to assist with disease diagnosis and staging, and may act as targets for therapies 
designed to lower oxidative stress in AD tissue.
In the human brain, multiple functions are reliant upon iron as a co-factor, including, but not limited to, neuro-
transmitter synthesis, ATP production and myelin sheath formation1,2. As a result, a basal level of brain iron is 
required to maintain healthy tissues and brain iron homeostasis is strictly regulated1–4. Despite playing a vital role 
in the brain, iron can convey toxic effects when stored incorrectly or when it adopts abnormal chemical states2,4–7. 
The ability of iron to readily change oxidation state is an essential property required for its biological functionality. 
However, this ability also leads to its potential toxicity as it allows iron participation in Fenton chemistry, resulting 
in the production of reactive oxygen species (ROS) which are capable of inducing oxidative stress and neuronal 
injury8–11.
As a fundamental component of iron homeostasis, mammals store brain iron within the ferritin protein com-
plex, in the form of a ferrihydrite-like mineral, (Fe3+)2O3•0.5H2O, a poorly crystalline ferric oxyhydroxide, typ-
ically accompanied by phosphate1,12–14. This form of storage prevents iron-associated ROS production, thereby 
protecting brain tissues from detrimental free radical burdens. Archetypal mammalian ferritin is comprised from 
two subunits: H-chain and L-chain chain ferritin, which assemble into a 24-subunit protein complex, ~450 kDa 
in molecular weight1,13,15,16. The complex is 12–13 nm in diameter, containing an 8 nm hollow core capable of 
storing up to 4500 Fe atoms13. Both H-ferritin and L-ferritin subunits have distinct functions that provide ferritin 
with an efficient means by which to store large numbers of iron atoms safely in vivo. H-ferritin (21 kDa) contains 
a di-iron binding site and possesses ferroxidase activity, catalysing the conversion of redox-active ferrous (Fe2+) 
iron into a redox-inactive ferric (Fe3+) state as it passes into the core. L-ferritin (19 kDa) does not possess any 
known enzymatic activity, but does contribute to long term iron storage, by accelerating the transfer of iron from 
the ferroxidase site to the ferritin core, whilst also stabilising ferritin’s complex structure1,12,13.
Evidence of disrupted iron homeostasis has been observed in the tissues of Alzheimer’s disease (AD) subjects, 
suggesting a link between altered iron handling in AD brain tissues and the development of the disorder2,4,6,7,17–22. 
AD is a progressive neurodegenerative disease that is the most common cause of dementia amongst the elderly 
and currently affects 5.4 million individuals in the USA alone19,23–25. The development of AD is heavily influenced 
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by age, and due to increasing average life-expectancy, the number of AD cases is projected to nearly triple by 
205025. The underlying cause of AD is poorly understood and currently no cure exists.
Pathologically, AD is characterised by the presence of two hallmark lesions: intracellular neurofibrillary tan-
gles comprised of hyperphosphorylated tau26,27, and extracellular plaques (also referred to as senile plaques) com-
prised primarily of the peptide β-amyloid (Aβ)28–30. Aβ is formed through cleavage of the amyloid precursor 
protein by secretase enzymes, resulting in the formation of multiple peptide isoforms varying in amino acid 
length28,31–37. The 42-amino acid isoform of the peptide is the most fibrillogenic, and is consequently most asso-
ciated with AD traits, such as senile plaques and neurotoxicity38. Although the extent to which Aβ contributes to 
the pathogenesis of AD is a topic of much debate, even concerning whether deposition of Aβ is a physiological 
response as opposed to an inherently pathological occurrence39, it is commonly accepted that Aβ accumulation 
in the brain parenchyma is a fundamental event in the development of the disorder28,31,40–42.
Mounting evidence shows increased levels of iron, including iron minerals, to be present within tissue areas 
displaying AD pathology when compared to disease-free controls20,21,43–51. Iron minerals containing iron cati-
ons in a low oxidation state, such as magnetite (Fe3O4) and pure ferrous (Fe2+) minerals (e.g. wustite), as well 
as zero-oxidation-state iron (Fe0), are capable of catalysing Fenton redox chemistry, driving the production of 
ROS and potentially inducing oxidative stress. Such low-oxidation-state iron phases are inherently unstable and 
thus not expected to be preserved in biological systems. However, it has been suggested that ferritin malfunction 
and/or the interaction of Aβ with naturally occurring iron stores may result in chemically-reduced iron pha
ses43,45,47,50–54. Indeed, ferritin has been shown to accumulate in Aβ plaque structures in vivo55, and increased 
levels of ferrous iron containing minerals have been recorded in pathological ferritin isolated from AD tissues 
compared to disease-free ferritin controls50.
Further evidence of iron accumulation within Aβ plaque structures has been demonstrated by HR-TEM 
where ferritin core-sized iron deposits with a crystal structure consistent with magnetite/maghemite were 
characterised embedded within extracted human amyloid plaque core material47; a result supported by more 
recent observations in other cases of Alzheimer’s disease56. Moreover, our recent synchrotron-based X-ray 
absorption studies have revealed the presence of nanoscale (ca. 200 nm) deposits of chemically-reduced iron 
within plaque structures located in the cortical tissue of APP/PS1 transgenic mice57, and amyloid plaque core 
material extracted from the grey matter in donated human brains from confirmed AD cases, including phases 
consistent with zero-oxidation-state iron in the latter58. These studies revealed dramatic nanoscale variations in 
iron oxidation state within the same amyloid plaque structures, highlighting the need for nanoscale resolution 
chemically-sensitive imaging in the investigation of metal biochemistry in living systems.
In addition, we previously demonstrated that the Aβ(1-42) peptide fragment is capable of chemically reduc-
ing unbound iron(III) oxyhydroxide and ferrihydrite to a pure ferrous phase in vitro59,60, whilst a recent in vitro 
spectrophotometric-based study has suggested that Aβ(1-40) can influence ferritin iron chemistry61. This evi-
dence strongly implicates Aβ in the formation of chemically-reduced iron phases in AD.
As increased levels of oxidative stress are characteristic of AD pathogenesis62–67, chemically reduced, 
redox-active iron may represent a target for therapies intended to lower oxidative burdens, thereby inhibiting dis-
ease progression68,69. Furthermore, as iron redox chemistry has a profound effect upon its physical (particularly 
magnetic) properties, identifying iron phases specifically associated with Aβ pathology could provide a clinical 
biomarker for non-invasive disease diagnosis via magnetic resonance imaging (MRI)70.
Despite this growing body of evidence, the manner in which Aβ influences iron chemistry, even within 
the protein encapsulated core, and the chemical by-products formed through Aβ/ferritin interaction, remain 
unclear. Acknowledging both that ferritin is the primary form of iron storage in the brain1, and that Aβ/ferritin 
co-localises within AD tissues55, studying the chemistry of Aβ/ferritin interaction is vital to understand how 
altered iron homeostasis may contribute to the development of AD.
In this study we employed scanning transmission X-ray microscopy (STXM), a synchrotron-based X-ray 
spectromicroscopy technique, to examine the interaction of Aβ(1-42) with ferritin, and establish whether this 
interaction could result in the formation of the nanoscale, chemically-reduced iron phases observed within amy-
loid structures in the brain. STXM is a powerful technique that allows the chemical speciation of a sample to be 
determined to a spatial resolution of ca. 20 nm. The capacity for combined nanoscale spatial and chemical sensi-
tivity, offered by STXM, is extremely important for investigations of amyloid/iron structures as the properties of 
inorganic inclusions have been shown to vary at the nanoscale.
Here, STXM was used to determine the distribution and chemical composition of protein and iron within in 
vitro-formed Aβ/ferritin aggregate structures at a nanoscale spatial resolution. We report a detailed characterisa-
tion of iron oxidation state formed through the interaction of Aβ and ferritin.
Results
As multiple different laboratory-based and synchrotron experiments were performed for this study, it was neces-
sary to use several different batches of the Aβ(1-42) peptide. For clarity, the different batches and associated inves-
tigations are explicitly listed in the Supplementary Information Table S1. The synchrotron work was performed 
using X-ray microscopes on two different synchrotron beamlines: PolLux at the Swiss Light Source; and I08 at 
the Diamond Light Source. As these instruments have slightly different performance characteristics (for example 
energy resolution), we have also stated in Table S1 which beamlines were used to obtain each dataset reported. All 
Aβ and ferritin incubations were performed under sterile conditions at 37 °C in a modified Krebs-Henseleit (KH) 
buffer medium (pH 7.4) containing physiologically relevant concentrations of Ca2+ and Mg2+ 59,60. Please refer to 
methods for further information regarding sample preparation/incubation.
Aβ(1-42) incorporates ferritin into amyloid aggregate structures. Time-lapse images of ferritin 
incubated for 18 hours in the presence and absence of Aβ are displayed in Fig. 1. When incubated in the absence 
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of Aβ, 1.3 µM ferritin formed a stable and uniform orange/brown colloidal dispersion that remained unchanged 
throughout the period of examination. Conversely when ferritin was incubated in the presence of 35 µM Aβ, 
dense orange precipitates formed after 15–20 minutes of interaction, suggesting the co-aggregation of Aβ and 
ferritin. Once formed, these precipitates remained unchanged over the 18 hours of imaging.
TEM images of Aβ aggregate structures formed in the absence and presence of ferritin are displayed in Fig. 2. 
Where Aβ was incubated in the absence of ferritin, amyloid aggregates composed of well-defined fibrillar struc-
tures were observed (Fig. 2a), consistent in morphology with fibrillar amyloid structures reported previously71. 
However, when Aβ was incubated with ferritin, amyloid aggregates appeared to be composed of poorly defined 
structures containing a high concentration of electron dense fine particles (Fig. 2b). The average diameter (6.1 
[±1.3] nm, n = 434) and morphology of these electron dense particles was similar to that of unstained ferritin 
standards imaged under TEM (6.8 nm [±1.1], n = 237); see Supplementary Fig. S1), where the electron dense 
regions correspond to ferritin’s iron oxide core. These TEM images suggest that Aβ had incorporated ferritin 
Figure 1. Time lapse images during incubation of ferritin and ferritin + Aβ. Images display ferritin (Ftn) 
incubated in the presence (left) and absence (right) of Aβ over an 18-hour period. Incubation times are shown 
to the left of each image.
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into its aggregate structures, complementing time lapse images of Aβ/ferritin suspensions where Aβ appeared to 
co-aggregate with ferritin (Fig. 1).
X-ray spectromicroscopy (STXM) of Aβ structures formed in the absence of ferritin across the carbon 
K-absorption edge (280–320 eV) provided an X-ray absorption spectrum (Fig. 3; red) closely resembling an albu-
min protein reference (Fig. 3; blue). STXM examination of ferritin structures across the carbon K-edge generated 
an X-ray absorption spectrum (Fig. 3; green) similar to both albumin and Aβ. Whilst sufficiently different amino 
acids/peptides provide distinct carbon K-edge spectra (see for example Kaznacheyev et al., and Boese et al.72,73), 
the subtle differences between Aβ and ferritin spectra meant that measurements at the carbon K-edge alone could 
not be used to distinguish between the two species.
Aβ/ferritin interaction leads to the chemical reduction of ferritin-stored iron. To confirm that the 
electron dense particles shown in Fig. 2b contained iron and to monitor the protein morphology and oxidation 
Figure 2. TEM images of Aβ/ferritin aggregate structures. Images display aggregates formed in (a) the absence 
and (b) the presence of ferritin (minimum 48 hours of co-incubation). Inset (bottom right) shows zoomed area 
highlighted in the yellow box.
Figure 3. Carbon K-edge X-ray absorption spectra of albumin, Aβ(1-42) and ferritin.
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state of iron within Aβ/ferritin aggregates over an extended incubation period (144 hours), Aβ/ferritin aggregates 
were studied by STXM at the Swiss Light Source on the PolLux beamline.
Following 0.5 and 48 hours of Aβ/ferritin co-incubation, multiple protein dense aggregates were observed 
using STXM. A representative example of an aggregate structure formed following 48 hours of incubation is 
shown in Fig. 4. TEM imaging of the aggregate revealed a poorly defined fibrillar structure containing electron 
dense fine particles widely spread throughout the aggregate (Fig. 4a–c), indicating the iron oxide core of ferritin 
was preserved.
Speciation-dependent contrast maps of the aggregate collected at the carbon K-absorption edge (Fig. 4d) in 
order to observe the protein distribution, and the iron L3-absorption edge (Fig. 4e), showed iron to be distrib-
uted throughout the entire aggregate structure, demonstrating the co-aggregation of Aβ and ferritin. A similar 
distribution of iron was observed within an Aβ/ferritin aggregate formed following 0.5 hours of incubation, as 
displayed in Supplementary Fig. S2.
Figure 4. TEM and STXM analysis of an Aβ/ferritin aggregate formed following 48 hours of co-incubation. 
(a-c) TEM images of the Aβ/ferritin aggregate. Uniformly distributed electron dense fine particles can be 
seen in the highest magnification image in (c). STXM speciation dependent maps (d-f) and an iron L2,3-edge 
X-ray absorption spectrum (g) from the aggregate. (d) Carbon K-edge protein map. (e) Iron L3-edge map. (f) 
Composite image displaying protein (green) and iron (red) content of the aggregate. (g) Iron L2,3-edge X-ray 
absorption spectrum from the iron content displayed in (e). The solid line for the spectrum corresponds to the 
best fit curve created by superposition of suitably scaled iron reference X-ray absorption spectra. (h) Reference 
iron L2,3 edge X-ray absorption spectra for ferric (ferritin standard; blue), ferrous (FeCl2; red), magnetite (Fe3O4; 
green) and elemental (Fe0; magenta) iron phases. Grey dashed and dotted lines indicate the energy positions of 
the principal Fe2+ and Fe3+ absorption peaks respectively. See also Supplementary Fig. S3 for additional ferritin 
iron L2,3-edge X-ray absorption spectra.
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To establish the precise chemical nature of the iron within the aggregate shown in Fig. 4, STXM examination 
was performed across the entire iron L2,3-absorption edge (700–740 eV). A non-linear least-squares fitting proce-
dure was employed for the iron L2,3-edge X-ray absorption spectra collected in this study to provide the relative 
proportion of the iron phases contributing to each spectrum. Reference iron L2,3-edge absorption spectra for iron 
in various oxidation states are provided in Fig. 4h. As differing ferric phases can provide subtly distinct L2,3-edge 
X-ray absorption spectra, thereby affecting fitting, a ferritin standard was used to fit the ferric component of the 
experimental iron L2,3-edge spectra to best represent the starting iron material.
Iron references were scaled for fitting as shown in our previous work (Everett et al.58), to enable accurate 
characterisation of the iron X-ray absorption spectra recorded here. The fit of the spectrum shown in Fig. 4g 
showed the iron content of the aggregate to be in an entirely ferric state, indistinguishable from ferritin standards 
(see Supplementary Fig. S3), indicating the preservation of ferritin’s ferric iron oxide core following 48 hours of 
incubation with Aβ.
Ferric materials provide an iron L2,3-edge absorption spectrum comprised of a dominant peak feature 
at 709.5 eV and a low intensity shoulder at 708 eV at the L3-absorption edge, and two further low intensity 
L2-absorption edge peaks at 721 and 723 eV, as shown in the reference spectrum in Fig. 4h (blue spectrum). 
The low-energy Fe3+ X-ray absorption feature at 708 eV occurs at the same energy as the principal iron L3-edge 
absorption feature for ferrous (Fe2+) and zero-oxidation-state (Fe0) materials. Examples of FeCl2 (red spectrum) 
and Fe0 (magenta spectrum) are shown in Fig. 4h. Therefore, increases in the Fe2+ and Fe0 content of an initially 
purely ferric iron material will manifest as an increase in the intensity of this 708 eV feature in relation to the 
principal L3-edge Fe3+ absorption peak at 709.5 eV. Likewise, at the iron L2-absorption edge, increases in Fe2+ 
and Fe0 content result in an increase in the intensity of the X-ray absorption feature at 721 eV with respect to the 
feature at 723 eV.
TEM and STXM images of an Aβ/ferritin aggregate formed following the full incubation period (144 hours) 
are displayed in Fig. 5. TEM images of this aggregate revealed a largely amorphous structure lacking any mature 
amyloid fibril structure (Fig. 5a,b), yet containing regions of short spiked fibrils. In contrast to the earlier time 
points, no electron dense fine particles were observed. STXM speciation mapping at the carbon K-absorption 
edge revealed this aggregate to be protein dense, in keeping with Aβ/ferritin structures formed following 0.5 and 
48 hours of Aβ/ferritin co-incubation. However, speciation mapping at the iron L3-absorption edge showed the 
iron content of this aggregate to be confined to a few discrete regions (Fig. 5d), the largest of which being approx-
imately 200 nm in diameter, rather than spatially correlated to the protein distribution of the aggregate as found 
in the earlier time points.
Iron L2,3-edge X-ray absorption spectra from an iron region and a time-matched ferritin control are shown in 
Fig. 5f. Examination of the ferritin control (Fig. 5f; blue) provided an X-ray absorption spectrum characteristic of 
a pure ferric phase, demonstrating that the oxidation state of iron in ferritin was maintained over the incubation 
period. In contrast, examination of an iron deposit within the Aβ/ferritin aggregate provided an X-ray absorption 
spectrum characteristic of a chemically-reduced iron phase (Fig. 5f; red). As can be seen by comparing with the 
Fe3O4 and Fe3+ standards shown in Fig. 4h (magnetite and ferritin respectively), enhanced magnetite features and 
diminished Fe3+ features were recorded across the iron L2,3-absorption edges. Fitting of the spectrum showed this 
area to be principally composed of magnetite (ca. 84%) with a minor contribution from Fe2+ (16%).
As no evidence of iron reduction was observed in either the ferrihydrite-like iron cores within ferritin alone, 
or in exposed nanoparticulate ferrihydrite time-matched controls incubated in identical buffer medium (blue 
trace in Fig. 5f and Supplementary Fig. S3C respectively), these alterations in iron chemistry appear to be due to 
the interaction of Aβ with ferritin.
Further TEM examination of sample material surrounding that shown in Fig. 5 provided evidence of a poorly 
fibrillar aggregate structure, similar to that shown in Fig. 4, demonstrating a heterogeneity in Aβ/ferritin aggre-
gate morphology at this incubation point (Supplementary Fig. S4).
Aβ/ferritin aggregates act as a site of carbonate deposition and calcium sequestra-
tion. Following our recent related observations of both calcium and carbonate within ex vivo human AD amy-
loid plaque cores using X-ray spectromicroscopy58, the protein, carbonate, calcium and iron contents of a further 
series of Aβ/ferritin incubations were investigated using the I08 beamline at Diamond Light Source, operating 
in the STXM mode. In these experiments, measurements were performed at the calcium L-edge (340–360 eV) in 
addition to the carbon K-edge and iron L2,3-edge.
STXM speciation maps and X-ray absorption spectra from Aβ/ferritin aggregates formed following a longer 
period of 240 hours of co-incubation are shown in Fig. 6. Protein speciation maps taken at 288.3 eV showed 
this region to contain both fibrillar-like and amorphous protein aggregates (Fig. 6a). The carbonate content of 
these aggregates was determined by performing speciation mapping at 290.5 eV; the energy corresponding to the 
absorption feature for carbonate at the carbon K-edge (see e.g. Figure 6i). Carbonate speciation mapping revealed 
that both fibrillar and amorphous aggregates contained carbonates, although the density of carbonate material 
was much higher in the amorphous structure (Fig. 6b).
To further investigate the origin of this carbonate material, speciation maps were performed at the calcium 
L2-absorption edge (352.6 eV). Calcium was found to be present in both fibrillar and amorphous aggregates with 
a higher density again being present in the amorphous structure (Fig. 6c). Furthermore, co-incident calcium and 
carbonate deposition was observed, suggesting at least some of the calcium present to be composed of calcium 
carbonate. However, the calcium distribution also extended beyond the carbonated areas, indicating additional 
calcium phases to be present.
Iron L3-absorption edge mapping (Fig. 6d) revealed the iron content of the fibrillar aggregate to be spread 
throughout the aggregate structure, closely following the protein morphology as was seen earlier in Fig. 4. 
Conversely, the iron distribution within the amorphous aggregate was found to be concentrated into dense 
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sub-micron foci, similar to that observed in the aggregate displayed in Fig. 5, where iron was found to be in a 
chemically-reduced state.
To further assess the oxidation state of the iron found within these aggregate structures, an iron oxidation 
state contrast map was created by subtracting the STXM image taken at 708 eV (the energy of the principal Fe2+ 
and Fe0 iron L2,3-edge absorption peak) from the image taken at 709.5 eV (the principal Fe3+ peak). The resulting 
contrast map shows Fe3+ as regions of light contrast, and Fe2+ or Fe0 as areas of dark contrast (Fig. 6e). From this 
oxidation difference map, it is apparent that the iron associated with the fibrillar aggregate structure was in a pre-
dominantly ferric state, whereas the dense particulate iron deposits within the amorphous protein structure were 
predominantly ferrous or zero-oxidation-state.
To investigate this amorphous aggregate in more detail, high resolution images of the region highlighted by 
the yellow box in Fig. 6e were taken across the carbon K-edge and the iron L2,3-edge (Fig. 6g–h,j–l). The resulting 
Figure 5. TEM and STXM analysis of an Aβ/ferritin aggregate formed following 144 hours of co-incubation. 
(a,b) TEM images of the Aβ/ferritin aggregate. STXM speciation dependent maps (c-e) and iron L2.3-edge 
X-ray absorption spectrum (f) from the aggregate. (c) Carbon K-edge protein map. (d) Iron L3-edge map. (e) 
Composite image displaying protein (green) and iron (red) content of the aggregate. (f) Iron L2.3-edge X-ray 
absorption spectra from the iron content displayed in (d) [red] and from a time-matched ferritin-only control 
[blue]. The solid lines for the spectrum corresponds to the best fit curve created by superposition of suitably 
scaled iron reference X-ray absorption spectra. See also Supplementary Fig. S4.
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Figure 6. STXM analysis of an Aβ/ferritin aggregate formed following 240 hours of co-incubation. (a) Carbon 
K-edge protein map showing fibrillar (Fib) and amorphous (Am) protein structures. (b) Carbon K-edge 
carbonate map. (c) Calcium L-edge map. (d) Iron L3-edge map. (e) Iron oxidation state difference map showing 
regions containing predominately ferric (Fe3+) iron as the bright regions, and those containing predominately 
ferrous and/or zero-oxidation-state (Fe2+/Fe0) iron as the dark regions. (f) Composite image displaying protein 
(green), carbonate (light blue), calcium (blue) and iron (red) content of the aggregate. High-resolution STXM 
speciation (g) carbon K-edge protein map and (h) carbon K-edge carbonate map. (i) Carbon K-edge X-ray 
absorption spectra from the areas identified in the protein map (g). (j) High-resolution iron L3-edge map. (k,l). 
Iron L3-edge maps of the areas highlighted in (j). (m) Iron L2.3-edge X-ray absorption spectra from the areas 
labelled in (k,l). The solid lines for the spectra correspond to the best fit curves created by superposition of 
suitably scaled iron reference X-ray absorption spectra. See Supplementary Fig. S2 Panel 2 for additional Aβ/
ferritin structures from this time point.
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carbon K-edge X-ray absorption spectra from region I1 (light blue trace, Fig. 6i) highlighted in Fig. 6g,h, showed 
the characteristic aromatic absorption peak at 285 eV and 1s-to-π* amide peak at 288.3 eV, confirming this amor-
phous aggregate to be composed of protein. Additionally, a carbonate absorption peak at 290.5 eV was observed 
in the X-ray absorption spectrum from region I2 (red trace, Fig. 6i), identified in the carbonate speciation map 
shown in Fig. 6h.
High resolution iron L3-edge speciation maps of this amorphous protein region revealed multiple small iron 
spots 200–500 nm in size (Fig. 6j–l). The iron L2,3-edge X-ray absorption spectra for these iron deposits are shown 
in Fig. 6m. From these spectra it appeared that the most dense iron region (labelled M1 in Fig. 6k) was composed 
of a strongly reduced form of iron. Fitting for this region indicated zero-oxidation-state iron (Fe0; see Fig. 4h, 
magenta for reference spectrum) to be the predominant phase (ca. 90%) with minor contributions from Fe3+ and 
Fe3O4. Although 708 eV corresponds to the principal iron L3-edge absorption feature for both Fe2+ and Fe0, the 
two phases are distinguishable by the broader line-shape for the Fe0 spectrum which lacks the splitting seen for 
oxide spectra, and the more prominent L2 peak and post-L2 edge absorption intensity for Fe0 (see Fig. 4h).
Interestingly the high resolution iron L3-edge speciation maps displayed in Fig. 6k,l showed further regions 
of iron deposition beyond the region identified in the lower resolution iron difference maps (Fig. 6d,e). Iron 
L2,3-edge absorption spectra from these further regions (labelled M2, M3 and M4) were also consistent with a 
heavily reduced iron phase. Fitting of these spectra showed all of these regions to be primarily composed of Fe0, 
with minor contributions from Fe3O4, Fe3+ and Fe2+. This confirmed that low-oxidation-state iron material was 
diffusely spread throughout the aggregate, as opposed to punctate sources which could conceivably be artefacts 
arising from external nanoparticulate sources. Further examples of Aβ/ferritin aggregates formed from this Aβ/
ferritin series following 240 hours of incubation are displayed in the Supplementary Fig. S2 (Panel 2). As was 
the case in Fig. 6, diffuse iron associated with these aggregates was found to be entirely ferric, whereas dense 
sub-micron iron deposits were found to be chemically reduced.
Discussion
From the data presented here, it is apparent that Aβ(1-42) interacts with ferritin in a manner that leads to the 
conversion of ferritin-encapsulated ferric iron into nanoscale deposits of chemically reduced iron. These find-
ings implicate an Aβ/ferritin interaction in the formation of the nanoscale ferrous-rich and zero-oxidation-state 
iron minerals previously observed in tissue from AD cases48–50, transgenic AD mouse tissues57, and isolated AD 
pathological structures47,58. In addition, Aβ/ferritin aggregates were shown to sequester calcium and act as a site 
of carbonate deposition, resembling such mineralised deposits found in AD amyloid plaque core material58.
Electron microscopy, time-lapse imaging and X-ray spectromicroscopy (STXM) demonstrated that 
co-incubation of Aβ(1-42) with ferritin, results in the accumulation of ferritin within Aβ-aggregate structures. 
Ferritin was found to be widely spread throughout amyloid aggregates over the first 48 hours of co-incubation, 
with X-ray spectromicroscopy speciation mapping showing that the iron content closely follows peptide mor-
phology, a finding in keeping with our previous in vitro examination of Aβ/ferrihydrite interaction (see Everett 
et al.59). The inclusion of ferritin within amyloid aggregates resulted in poorly defined peptide structures when 
compared to Aβ incubated in isolation. This dependence of Aβ fibril morphology on the presence/absence of fer-
ritin may arise through interactions between the two species (potentially influencing the formation of secondary 
and tertiary Aβ structures), and/or through localized variations in peptide concentration arising from the rapid 
co-aggregation of Aβ and ferritin as shown in Fig. 1. The ability of Aβ to accumulate and incorporate ferritin into 
its structure as found here, also provides an explanation for observations made by Grundke-Iqbal et al. where 
ferritin was observed to be co-localised with senile plaque material in AD tissues55.
Prolonged incubation of Aβ(1-42) with ferritin under sterile conditions over longer time periods of 144–
240 hours led to the observation of both poorly defined fibril structures (as observed over the first 48 hours of 
incubation) and amorphous aggregate structures. TEM imaging of these amorphous structures showed a lack 
of amyloid fibril morphology, coupled with an absence of the electron-dense particulate material that would 
indicate intact ferritin. This is consistent with either disruption of the ferritin structure and/or the removal of the 
iron oxide core from the ferritin cage (the ferritin iron oxide core provides the strong TEM contrast in unstained 
images). As mature amyloid fibril structures were observed when Aβ was incubated in the absence of ferritin, and 
electron-dense cores indicating intact ferritin were maintained when ferritin was incubated in isolation, these 
alterations to amyloid structure appear to be a direct result of the Aβ-ferritin interaction.
STXM speciation mapping showed that the iron distribution within aggregate structures formed following 
144–240 hours of incubation varied dramatically, and depended on amyloid morphology. Where aggregates were 
composed of poorly defined fibrils, iron was diffusely spread throughout the aggregate, closely following protein 
distribution. Conversely, where aggregates were present in an entirely amorphous state, iron was no-longer dif-
fusely spread throughout the aggregate, instead being localised into dense foci. Examination of aggregate struc-
tures across the entire iron L2,3-absorption edge demonstrated the oxidation state of ferritin-derived iron to also 
be dependent upon both amyloid and iron morphology. Where the amyloid and iron content was “fibrillar” in 
nature, iron was found to remain in a ferric state. However, in amorphous amyloid aggregates where iron was 
localised in dense deposits hundreds of nanometers in diameter, iron was in a chemically-reduced state. Thus, 
through the use of STXM we provide the first descriptions of intra-sample variations in amyloid morphology 
dependent upon iron oxidation state, heterogeneity which is undetectable with standard bulk sample measure-
ments of fibril formation.
This association between amyloid aggregate morphology and iron oxidation state was reproducibly observed 
across multiple, independent, Aβ/ferritin incubation series, examined at different X-ray spectromicroscopy 
beamlines, and using different starting batches of Aβ. Fitting of the iron L2,3-edge absorption spectra from these 
chemically-reduced iron regions showed the presence of a magnetite-like ferrous-rich material and an addi-
tional further-reduced iron phase with absorption features consistent with zero-oxidation-state iron. These 
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Fe0 phases are analogous to those we reported in our ex vivo examination of amyloid plaque material extracted 
from AD grey matter, suggesting a similar phase to be present58. As no evidence of reduced iron was observed 
where ferritin or ferrihydrite was incubated in the absence of Aβ, the creation of a reducing environment and 
changes in iron chemistry appear to be driven by the co-aggregation of Aβ and ferritin. The absence of detectable 
low-oxidation-state iron in the ferritin controls also demonstrates that the chemically-reduced iron observed 
within the Aβ/ferritin aggregates is unlikely to be from iron bound to the external surface of ferritin, where sur-
face iron can arise as an artefact of ferritin purification.
The identification of nanoscale deposits of chemically-reduced iron further demonstrates the necessity for 
chemically-sensitive nanoscale resolution microscopy when examining the chemistry of Aβ/iron interactions. 
These deposits would not have been detected using bulk measurements or microfocus microscopy, where the 
signal from the reduced iron phases would have been lost in the prevailing signal arising from oxidized iron.
The ability of Aβ to influence the chemical composition of ferritin’s ferrihydrite core, resulting in the forma-
tion of a chemically-reduced iron phase, is entirely consistent with our previous X-ray based in vitro experiments 
where Aβ(1-42) was shown to induce the chemical reduction of ferric oxyhydroxide and ferrihydrite into a pure 
ferrous phase59,60. Our previous experiments were conducted using iron oxide phases directly exposed to Aβ. It 
was not known if ferritin-encapsulated ferric iron oxide cores could be affected, although our original study of 
iron oxide nanoparticles in extracted amyloid plaque cores pointed to ferritin as a potential source of the iron due 
to the size distribution of the measured particles47. In the present work, for the first time, Aβ(1-42) was shown to 
indeed be capable of influencing the redox chemistry of iron originating within the ferritin protein. Our previous 
and present findings parallel a recent in vitro study by Balejcikova et al. who utilised spectrophotometry to record 
a moderate increase in Fe2+ iron content when a different peptide fragment, Aβ(1-40) was incubated with ferritin, 
compared to where ferritin was incubated in isolation61.
What remains unclear is whether these changes to ferritin iron oxidation state occur whilst iron remains 
within the ferritin cage (i.e. electron transfer across the apoferritin protein as described in Watt et al.)74, or 
whether iron must first be extracted from the ferritin cage before reduction can take place. In either scenario, 
these changes would appear to be dependent on Aβ amyloid interaction with ferritin. Time-matched control 
experiments conducted in the absence of Aβ showed no evidence of iron leaching from the ferritin-cage, or of 
chemically-reduced iron (i.e. only ferric iron was detected).
In vitro evidence shows the reduction of ferritin-encapsulated iron to a ferrous state to be an effective method 
for the removal of iron from the ferritin cage16. If the Aβ/ferritin interaction creates an environment in which iron 
is chemically-reduced via electron transfer across the ferritin cage, iron may be exuded from ferritin, leading to an 
increased labile iron pool. Iron located in channels near the surface of the ferritin protein cage, critically involved 
in the transfer of iron between transferrin and ferritin, may represent a physiologically relevant iron source, sus-
ceptible to Aβ-mediated reduction75,76. Indeed, this iron has been shown to be rapidly extracted from ferritin by 
the iron chelator desferrioxamine75,76. This highlights the clinical importance of determining if ferritin protein 
quantified as a measure of iron status has retained its iron or whether it is effectively apoferritin77. In this context, 
quantifying apoferritin:ferritin levels (for example in the CSF) might have potential as a marker for amyloid/
ferritin interaction in vivo. Additionally, the low level of free-iron we recorded in the starting ferritin suspensions 
may have acted for a seed for Aβ-mediated iron reduction, in a manner similar to our previous studies59,60. This 
scenario is certainly possible in vivo, should the ferritin protein cage be compromised, thereby exposing the fer-
ritin iron core.
Under normal conditions in vivo, where iron homeostasis is well-managed, intracellular ferritin expression 
depends on levels of intracellular labile iron. If Aβ has the capacity to disrupt ferritin storage resulting in the 
chemical reduction and release of iron, it is conceivable that this could compromise intracellular iron metabolism 
to the extent that antioxidant defences are overwhelmed. The observation of chemically-reduced iron as dense 
iron foci is also consistent with the iron nucleation processes observed during the chemical synthesis of mixed 
valence78 and zero-oxidation-state iron nanoparticulates from unbound ferric iron precursors79.
Whilst these findings clearly show Aβ interaction with ferritin results in the chemical reduction of 
ferritin-derived iron, the reductant itself is still to be confirmed. Aβ may act as a reducing agent for iron in a 
manner akin to that originally proposed by Huang et al.10, with this possibility currently under further investiga-
tion. Alternatively, the co-aggregation of Aβ with ferritin could result in the formation of highly-localised com-
partments in which reactants capable of influencing ferritin-iron chemistry can accumulate. A possible example 
for this scenario is the blocking of ferritin’s hydrophilic channels by Aβ, preventing the escape of reactants 
such as superoxide radicals (formed at the ferritin ferroxidase centres), resulting in the chemical reduction of 
ferritin-iron. Indeed, the chemical reduction and subsequent release of ferritin iron via a superoxide-dependent 
mechanism has been demonstrated in vitro80,81.
These results suggest that not only labile iron pools but also ferritin-encapsulated iron may act as a source of 
chemically-reduced forms of iron in AD tissue. This may account for the increased levels of low-oxidation-state 
iron derived from ferritin isolated from AD tissues50, the ferritin-core sized magnetite-like deposits previously 
identified within amyloid plaque material using HR-TEM47, and the magnetite particles of proposed biogenic 
origin recorded in human brain tissues through isothermal resonance magnetisation experiments82. This mecha-
nism is far from implausible, as shown through the artificial production of chemically-reduced iron nanoparticles 
within the apoferritin cage, by first removing the natural ferritin core by iron reduction, with the subsequent use 
of iron Fenton chemistry to biomineralise the new magnetite nanocrystals83.
Ferritin is abundant throughout the human brain1,12, and has been observed to accumulate in localised regions 
of Aβ deposition55,84, whilst microglia, known to secrete the ferritin protein85, have also been associated with 
senile plaques in AD tissues55 providing potential routes for ferritin to interact with Aβ structures in vivo. Further 
evidence of ferritin accumulation in regions of Aβ pathology has recently been shown in 5XFAD transgenic 
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mouse hippocampal tissue, where antibodies specific for ferritin were found to accumulate in brain regions with 
both increased ferritin expression and a high loading of Aβ plaques86.
Interactions between aggregating Aβ and ferritin may represent significant sources of localised oxidative stress 
in AD tissue, potentially contributing to the neurodegeneration associated with AD8,9,62–64. It is noteworthy that 
others have previously observed associations between ferritin and aberrant tau filament structures as observed in 
AD and progressive supranuclear palsy patients, and that disruption to the function of ferritin can be detrimen-
tal to the many iron-dependent functions in the brain, in extreme cases (such as neuroferritinopathy) proving 
fatal84,87–92.
The association of largely amorphous amyloid structures with the occurrence of chemically-reduced iron 
deposits several hundred nanometers in diameter as observed here, was also reported in our X-ray spectromi-
croscopy examination of cortical tissue from APP/PS1 mice57, and isolated amyloid plaque material from AD sub-
jects58; suggesting that Aβ/ferritin interaction may have acted as source for the formation of chemically-reduced 
iron in these instances. The identification of differing amyloid/ferritin aggregate subtypes ([i] fibrillar amyloid 
aggregates containing diffuse ferric iron, [ii] amorphous amyloid aggregates containing dense chemically-reduced 
iron), indicates that the chemical state of amyloid-associated iron may reflect the type of amyloid aggregate that 
has formed (Table 1).
In addition to alterations in native iron chemistry, STXM examination of Aβ/ferritin aggregates formed fol-
lowing 144–240 hours of interaction at the carbon K-edge revealed the presence of additional carbon contain-
ing species. Regions of carbonate were located in Aβ/ferritin structures demonstrating carbonate to have been 
deposited during the co-aggregation of Aβ and ferritin, with protein N-terminal carbonates or dissolved CO2 as 
a potential source. As calcium was present in the buffer, examination of the amorphous Aβ/aggregate structure 
formed following 240 hours of incubation (shown to contain low-oxidation-state iron) was also performed at the 
calcium L-edge. Calcium L-edge speciation mapping revealed co-localised carbonate and calcium deposition, 
suggesting carbonate material to be comprised of calcium carbonate. Calcium carbonate formation therefore 
appears to be linked to Aβ/ferritin interaction.
Remarkably, this pattern of calcium mineralisation, carbonate loading, and nanoscale regions of 
low-oxidation-state iron formation within Aβ/ferritin aggregates structures is entirely consistent with that 
observed in amyloid plaque core material extracted from individuals with confirmed AD, as recently reported by 
our group58. These striking similarities are displayed in the comparison Fig. S5 of the Supplementary Information. 
This suggests that amyloid plaques may be formed through a similar process of Aβ/ferritin interaction in the 
presence of calcium in vivo. In particular, the characteristic features of dense amorphous peptide aggregates con-
taining deposits of Fe2+, magnetite or Fe0, were replicated in the ex-vivo plaque core material.
In conclusion, the data presented here demonstrate that the interaction of Aβ with ferritin in a physiolog-
ically relevant buffer medium results in the formation of dense amorphous amyloid structures harbouring 
chemically-reduced iron. This points towards Aβ/ferritin interaction as a probable source of the increased levels 
of mixed oxidation state Fe2+ and Fe0 phases previously observed within brain tissue from the APP/PS1 model of 
AD, in human AD tissue, and in isolated amyloid plaque cores47–49,57,58,93. Furthermore, the chemical composition 
of the in vitro aggregates formed in this study was shown to be analogous to primary components of the amyloid 
plaque core material extracted from the grey matter of AD subjects58, consistent with Aβ/ferritin interaction 
playing a prominent role in the development of iron-bearing amyloid deposits in vivo.
Given the abundance of ferritin throughout the human brain1, the capacity for Aβ to create an environment in 
which ferritin iron is chemically reduced, could lead to the sustained production of excess ROS, and therefore to 
Sample Type
Incubation 
Time (hrs) Aβ morphology Iron Distribution Iron oxidation state
Calcium 
Loading
Carbonate 
Loading
Aβ(1-42) All time points Fibrillar N/A N/A — None
Ferritin All time points N/A N/A Ferric (Fe3+) — None
Aβ(1-42) +Ferritin
0.5 Fibrillar
Uniform 
throughout 
aggregate
Ferric (Fe3+) — —
48 Fibrillar
Uniform 
throughout 
aggregate
Ferric (Fe3+) — —
144 Fibrillar
Uniform 
throughout 
aggregate
— — —
Amorphous Localised deposits (sub micron)
Mixed Valence (Fe2+/
Fe3+) — —
240 Fibrillar
Uniform 
throughout 
aggregate
Ferric (Fe3+) Low Low
Amorphous Localised deposits (sub micron)
Mixed Valence (Fe2+/
Fe3+)/Zero Valence 
(Fe0)
High High
Table 1. Summary of the differing aggregate types observed in this study. Identified iron phases and the 
presence of calcium and carbonate loading are shown for the cases where such measurements were obtained. 
“—” denotes not measured.
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oxidative stress in AD tissues. With oxidative stress being a key characteristic of AD pathology62,63,65,94, this inter-
action could represent a target for therapies intended to lower oxidative burdens and delay disease progression, 
either through targeting Aβ-induced low-oxidation-state iron phases, or by preventing Aβ from interacting with 
ferritin and so averting the formation of chemically-reduced iron. Moreover, as specific iron and calcium phases 
provide marked and quantifiable impact on MRI contrast, it is possible that forms of iron and calcium preferen-
tially associated with amyloid deposits could be used as endogenous markers to facilitate screening for amyloid 
deposition in at-risk populations, before clinical manifestations arise.
Methods
the interaction of Aβ and Ferritin. Preparation of Aβ/ferritin Suspensions. Horse spleen ferritin 
(Type I; 125 mg/mL; 1% saline solution) was purchased from Sigma Aldrich and stored at 4 °C until time of 
use. Characterisation of ferritin size, crystal structure, oxidation state and iron content are provided in the 
Supplementary Information (Figs. S1, S3 and S6). Ferritin was diluted in a modified Krebs-Henseleit (KH) buffer 
(pH 7.4; 100 mM PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid), 118.5 mM NaCl, 4.8 mM KCl, 1.2 mM 
MgSO4, 1.4 mM CaCl2, 11 mM glucose) to achieve a 0.7 mg/mL (440 µM iron) ferritin suspension. KH buffer was 
made on the day of use, and was filtered (0.2 µm pore size) in sterile conditions prior to use, to inhibit bacterial 
growth. This buffer medium, modelled on the cerebral spinal fluid which bathes the brain, contains physiolog-
ically relevant concentrations of Ca2+ and Mg2+, both of which have been shown to influence amyloid peptide 
aggregation dynamics95,96. The buffer PIPES was chosen as it does not strongly interact with metal ions97.
Synthetic monomeric Aβ(1-42) (Bachem) was thawed and dissolved in 1 mM NaOH (Sigma Aldrich) to create 
a 1 mg/mL (220 μM) stock. Aβ stock was allowed to sit at room temperature for 30 minutes to ensure complete 
peptide dissolution before being added to 0.7 mg/mL ferritin suspensions in KH buffer under sterile conditions. 
Final ferritin and Aβ concentrations were 0.6 mg/mL (1.3 µM, 370 μM iron content) and 0.16 mg/mL (35 μM) 
respectively. A ferritin concentration of 0.6 mg/mL was used as this value corresponded to the iron concentration 
used in our previous in vitro experiments examining Aβ interaction with ferric iron59,60. This ferritin concentra-
tion ensures sufficient iron is present to enable detection of iron using X-ray spectromicroscopy when employing 
the sampling technique described below. Aβ-free ferritin controls were created as above, with the substitution 
of 1 mM NaOH for Aβ. 35 μM Aβ solutions were prepared in KH buffer as an amyloid reference. 370 µM 6-line 
ferrihydrite suspensions were prepared in KH buffer as an unencapsulated iron reference. Ferrihydrite was syn-
thesised as described in Schwertmann et al.98.
Incubation of suspensions. All suspensions/solutions were incubated under aerobic conditions at 37 °C within 
sealed microcentrifuge tubes until the time of sampling. For time lapse imaging a camera was mounted inside 
the incubator, allowing images of Aβ/ferritin suspensions to be taken in situ without physical manipulation of the 
sample tubes. Time lapse images demonstrating the precipitation of ferritin by Aβ were created using Lapse it™ 
time lapse software. Images of microcentrifuge tubes containing Aβ/ferritin and a ferritin only control were taken 
over a period of 18 hours.
The incubation of ferritin suspensions in KH buffer did not result in the leaching of ferritin iron, as 
demonstrated through iron quantification measurements performed over a 240 hour incubation period (see 
Supplementary Information).
Scanning Transmission X-ray Microscopy Sample Preparation. 15 μL of Aβ/ferritin suspensions were depos-
ited onto either silicon oxide membranes (DuneSciences; 75 nm thickness) or silicon nitride membranes (Agar 
Scientific; 75 nm thickness) and excess liquid was removed using filter paper. For the Aβ/ferritin series examined 
on the PolLux beamline at the Swiss Light Source sampling was performed following 0.5, 48 and 144 hours of 
incubation. An additional Aβ/ferritin series was examined using the I08 beamline at Diamond Light Source, with 
sampling being performed following 240 hours of incubation. Additional Aβ and ferritin control samples were 
examined to provide reference carbon K-edge and iron L-edge reference X-ray absorption spectra.
As STXM was the primary technique employed to assess iron oxidation state following Aβ/ferritin incuba-
tion, conscientious effort was taken to maintain anoxic conditions during sampling, transfer and examination 
of Aβ and ferritin materials. All STXM samples were prepared within a nitrogen filled glove bag (Glas-col), 
and membranes containing Aβ/ferritin structures were stored within a nitrogen filled O-ring sealed jar (Oxoid) 
to prevent changes in iron oxidation states. Membranes were mounted onto STXM sample holders for X-ray 
spectromicroscopy. Sample mounting was conducted within a nitrogen filled glove bag. Anoxic conditions were 
maintained during sample transportation by using a nitrogen filled vessel for sample transfer and purging of the 
STXM endstation with nitrogen prior to sample loading.
Electron microscopy sample preparation. Small volumes of Aβ/ferritin suspensions were deposited onto carbon/
formvar coated copper TEM grids and excess liquid removed. Samples were taken following 0.5, 48, 96 and 
144 hours of incubation.
X-ray spectromicroscopy: scanning transmission X-ray microscopy. X-ray spectromicroscopy was performed at 
the Swiss Light Source on the PolLux beamline using the STXM endstation, and at the Diamond Light Source 
on beamline I08. Focussed X-ray spot size was approximately 20 nm on the PolLux beamline and 50 nm on I08. 
Energy-specific images of sample material were created by raster scanning the sample across a focussed X-ray 
beam and recording the intensity of the transmitted X-rays. To minimise potential photoreduction effects caused 
by the incident X-ray beam thereby preserving native sample chemistry, scanning (exposure) times were kept to 
a minimum (typically 1–2 ms per point).
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To create contrast maps displaying the chemical speciation of a given sample material, paired images were 
taken at the energy of a feature of interest (e.g. the main ferric (Fe3+) iron peak in the Fe L3-edge absorption 
region) and a few eV below this feature. The “off-peak” images were then subtracted from the “on-peak” images 
revealing the chemical speciation for the examined sample region.
X-ray absorption spectra were collected by taking a series of images (called a stack) of a region of interest at 
multiple energies across a desired energy range (e.g. the iron L2,3-absorption edge [700–740 eV], or the carbon 
K-absorption edge [280–310 eV]). Transmitted X-ray intensities for the stack images were converted to optical 
density using background regions that did not contain any sample material, thereby removing background X-ray 
absorption features attributable to the beamline. This method of spectromicroscopy allows an X-ray absorption 
spectrum to be created from every pixel of a stack image, thus allowing spectral information to be realised from 
highly localised regions of interest.
Carbon K-edge X-ray spectromicroscopy was performed prior to higher energy iron L2,3-edge examination 
as to minimize X-ray beam induced damage to carbon structures. Only a sub-set of Aβ/ferritin structures were 
examined using STXM due to experimental time constraints.
X-ray spectromicroscopy data were processed using the aXis 2000 software package (http://unicorn.mcmaster.
ca/aXis2000. html). The brightness and contrast of X-ray microscopy images were adjusted using ImageJ software. 
Grey scale X-ray microscopy images were converted to false colour before being recombined as overlays to create 
coloured composite images.
Transmission electron microscopy. Transmission electron microscopy (TEM) was performed using a 
JEOL 1230 microscope operating at 100 kV. A low operating energy was used to minimise electron beam damage 
of sample materials. No positive or negative stains were used during TEM microscopy. Where both techniques 
were employed, TEM was performed following STXM examination to prevent electron beam induced changes 
to sample chemistry.
Quantification and statistical analysis. Analysis of X-ray Absorption Spectra. To estimate the relative 
proportion of iron phases contributing to the iron L2,3-edge X-ray absorption spectra measured in these experi-
ments, iron L2,3-edge X-ray absorption spectra were fitted to reference X-ray absorption spectra from Fe3+, Fe2+, 
Fe3O4 and Fe0 standards using non-linear least squares fitting procedures. Accurate scaling of these standards was 
required to provide precise quantitative determination of the phase proportions contributing to the experimental 
data. The scaling factors were determined by normalising the X-ray absorption intensity for each reference iron 
phase to the integrated intensity over the iron L2,3 absorption edges, as described in our previous work (see Everett 
et al.58). An iron L2,3-edge X-ray absorption spectrum from a ferritin standard was used for fitting the Fe3+ con-
tribution to the experimental iron L2,3-edge X-ray absorption spectra. The absorption features from this ferritin 
spectrum are consistent with a pure ferric phase, and it was therefore chosen as a suitable ferric (Fe3+) standard 
for fitting. The Fe0 reference spectrum used for fitting was obtained from Fe0 film standards prepared and meas-
ured under vacuum to prevent oxidation99.
Data availability
The datasets generated during and/or analysed during the current study are available through the Keele Research 
Repository at https://eprints.keele.ac.uk.
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